Wilde, C
Poostchi, A
Mehta, R L
MacNab, H K
Hillman, J G
Vernon, S A
Amoaku, W M
Article History
Received: 5 March 2016
Accepted: 24 November 2016
First Online: 10 March 2017
Competing interests
: Winfried M Amoaku: Consultant for Alimera, Allergan Inc, Bayer, Novartis, Pfizer, Santen, and Thrombogenics, and has undertaken research sponsored by Allergan, Novartis, and Pfizer. He has received speaker fees and travel grants from Allergan, Bausch and Lomb, Bayer, Novartis and Pfizer. Stephen A Vernon: Consultant for Allergan and Alcon, and has undertaken research sponsored by Allergan and Pfizer. He has received speaker fees from Allergan, Alcon, Pfizer, Optivue and Topcon. The remaining authors declare no conflict of interest.